-
Innovation Ranking
NewInnovation Ranking – iBio Inc
iBio Inc (iBio) is a biotechnology company. It develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. Its pipeline products includes IBIO-100, IBIO-202 for Covid-19 and IBIO-400 for classical swine fever. The company's IBIO-100 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis, among others. In addition, it is producing animal-free proteins using the FastPharming System. iBio offers CDMO services comprise of process development, cGMP manufacturing, aspetic fill,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Lupus Nephritis Drug Details: Ravulizumab (Ultomiris) is a...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pemphigus Vulgaris – Drugs In Development, 2023
Global Markets Direct’s, ‘Pemphigus Vulgaris - Drugs In Development, 2023’, provides an overview of the Pemphigus Vulgaris pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Plague – Drugs In Development, 2023
Global Markets Direct’s, ‘Plague - Drugs In Development, 2023’, provides an overview of the Plague pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pemphigus – Drugs In Development, 2023
Global Markets Direct’s, ‘Pemphigus - Drugs In Development, 2023’, provides an overview of the Pemphigus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pemphigus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drugs In Development, 2023’, provides an overview of the Granulomatosis with Polyangiitis (Wegener's Granulomatosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...